# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7...
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price tar...
UBS analyst Colin Bristow maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and lowers the price target from $3.5 ...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the pr...
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price tar...
BioXcel Therapeutics shares topline results from an Igalmi (dexmedetomidine) sublingual film study. The 180 mcg dose demonstrat...